Remission of cold hemagglutinin disease induced by rituximab therapy [1]

CMAJ. Canadian Medical Association Journal

Volumn 164, Issue 10, 2001, Pages 1405-

  Sparling, T G ^a   Andricevic, M ^a   Wass, H ^a  

^a Sheikh Khalifa Surgical Pavilion   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CHLORAMBUCIL; CYCLOSPORIN A; FOLIC ACID; HEMAGGLUTININ; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB;

ADULT; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; COLD HEMAGGLUTININ DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; HEMAGGLUTINATION; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; LETTER; LYMPHOMA; MALE; REMISSION;

EID: 0034909628     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Rituxan in the treatment of cold agglutinin disease
2. Remission of severe cold agglutinin disease after rituximab therapy
3. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to four-dose treatment program